Uğur KOSTAKOĞLU, Sedat SAYLAN, Gürdal YILMAZ, Mevlüt KARATAŞ, Serap İSKENDER, Firdevs AKSOY

Cost analysis and evaluation of nosocomial infections in intensive care units

Background/aim: The purpose of this study was to evaluate nosocomial infections occurring in our hospital intensive care units (ICUs) and the risk factors for these, and to determine the effect of these infections on mortality and cost. Materials and methods: This retrospective study was performed via infection control committee surveillance data, ICU records, and information processing data between 1 January and 31 December 2013 at the Kanuni Education and Research Hospital. Results: A total of 309 nosocomial infections were observed in 205 out of 566 patients. The density of nosocomial infections was 25.4 in 1000 patient days. Hospitalization was prolonged, and APACHE II and Charlson comorbidity scores were high in patients developing nosocomial infections (P < 0.001). Of the patients diagnosed with a nosocomial infection, 170 died. Infections were determined as the cause of death in 62 (36.5%) of the nonsurviving patients with a nosocomial infection. Acinetobacter baumannii was identified in 46 (74.2%) of the patients that died from nosocomial infections. The mean cost in patients developing a nosocomial infection was 15,229.30 Turkish lira (TL), compared to 9648.00 TL in patients without a nosocomial infection (P = 0.002). Conclusion: Regular infection control education sessions need to be held and the number of nurses needs to be increased in order to be able to reduce this high mortality, morbidity, and cost.

PDF

___

1. Halpern NA, Pastores SM, Greenstein RJ. Critical care medicine in the United States 19852000: an analysis of bed numbers, use and costs. Crit Care Med 2004; 32: 1254-1259.
2. Mayr VD, Dünser MW, Greil V, Jochberger S, Luckner G, Ulmer H, Friesenecker BE, Takala J, Hasibeder WR. Causes of death and determinants of outcome in critically ill patients. Crit Care 2006; 10: R154.
3. Horan T, Andrus M, Dudeck M. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36: 309-332.
4. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: A severity of disease classification system. Crit Care Med 1985; 13: 818-829.
5. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
6. Trilla A. Epidemiology of nosocomial infections in adult intensive care units. Intensive Care Med 1994; 20: 1-4.
7. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect Control Hosp Epidemiol 2000; 21: 510- 515.
8. Leblebicioglu H, Rosenthal VD, Arikan OA, Ozgültekin A, Yalcin AN, Koksal I, Usluer G, Sardan YC, Ulusoy S. Turkish Branch of INICC. Device-associated hospital-acquired infection rates in Turkish intensive care units. Findings of the International Nosocomial Infection Control Consortium (INICC). J Hosp Infect 2007; 65: 251-257.
9. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, NicolasChanoin MH, Wolff M, Spencer RC, Hemmer M. The prevalence of nosocomial infection in intensive care units in Europeresults of the European Prevalence of Infection in Intensive Care (EPIC) study. JAMA 1995; 274: 639-644.
10. Esen S, Leblebicioglu H. Prevalence of nosocomial infections at intensive care units in Turkey: a multicentre 1-day point prevalence study. Scand J Infect Dis 2004; 36: 144-148.
11. Dudeck MA, Weiner LM, Allen-Bridson K, Malpiedi PJ, Peterson KD, Pollock DA, Sievert DM, Edwards JR. National Healthcare Safety Network (NHSN) report, data summary for 2012, deviceassociated module. Am J Infect Control 2013; 41: 1148-1166.
12. Leblebicioglu H, Erben N, Rosenthal V, Atasay B, Erbay A, Unal S, Senol G, Willke A, Ozgültekin A, Altin N et al. International Nosocomial Infection Control Consortium (INICC) national report on device-associated infection rates in 19 cities of Turkey, data summary for 2003-2012. Ann Clin Microbiol Antimicrob 2014; 13: 51.
13. Sencan I, Kalayci MZ, Kabasakal E, Callak Oku F, Cetinkaya Sardan Y, Ascioglu S. T.C. Sağlık Bakanlığı, Ulusal Hastane Enfeksiyonları Sürveyans Agı (UHESA) Raporu Özet Veri. Ankara, Turkey: T.C. Sağlık Bakanlığı; 2013 (in Turkish).
14. Osman MF, Askari R. Infection control in the intensive care unit. Surg Clin North Am 2014; 94: 1175-1194.
15. Yilmaz G, Caylan R, Aydin K, Topbas M, Koksal I. Effect of education on the rate of and the understanding of risk factors for intravascular catheter-related infections. Infect Control Hosp Epidemiol 2007; 28: 689-694.
16. Freestone PP, Hirst RA, Sandrini SM, Sharaff F, Fry H, Hyman S, OCallaghan C. Pseudomonas aeruginosa-catecholamine inotrope interactions: a contributory factor in the development of ventilator-associated pneumonia? Chest 2012; 142: 1200- 1210.
17. Raffin TA. Intensive care unit survival of patients with systemic illness. Am Rev Respir Dis 1989; 140: 28-35.
18. Simonetti A, Ottaiano E, Diana MV, Onza C, Triassi M. Epidemiology of hospital-acquired infections in an adult intensive care unit: results of a prospective cohort study. Ann Ig 2013; 25: 281-289 (in Italian with English abstract).
19. See I, Lessa FC, ElAta OA, Hafez S, Samy K, El-Kholy A, El Anani MG, Ismail G, Kandeel A, Galal R et al. Incidence and pathogen distribution of healthcare-associated infections in pilot hospitals in Egypt. Infect Control Hosp Epidemiol 2013; 34: 1281-1288.
20. Yıldırım MI, Tuğrul HM. Assessment of efficacies of imipenem, cefoperazone-sulbactam and cefepime in rats with experimental thigh abscess model with multidrug resistant and susceptible Acinetobacter baumannii strains. Mikrobiyol Bul 2011; 45: 422-429 (in Turkish with English abstract).
21. Akın A, Çoruh AE, Alp E, Canpolat DG. Anestezi Yoğun Bakım Ünitesinde beş yıl içerisinde gelişen nozokomiyal enfeksiyonlar ve antibiyotik direncinin değerlendirilmesi. Erciyes Tıp Derg 2011; 33: 7-16 (in Turkish).
22. Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill 2008; 13: 47.
23. Karabay O, Yahyaoğlu M, Oğütlü A, Sandıkçı O, Tuna N, Ceylan S. Factors associated with mortality in Acinetobacter baumannii infected intensive care unit patients. Mikrobiyol Bul 2012; 46: 335-337 (in Turkish with English abstract).
24. Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, Karaman SO. In vitro activities of non- traditional antimicrobials alone or in combination against multidrugresistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents 2006; 27: 224-228.
25. Yalcin AN, Hayran M, Unal S. Economic analysis of nosocomial infections in a Turkish university hospital. J Chemother 1997; 9: 411-414.
26. Astagneau P, Fleury L, Leroy S, Lucet JC, Golliot F, Régnier B, Brücker G. Cost of antimicrobial treatment for nosocomial infections based on a French prevalence survey. J Hosp Infect 1999; 42: 303-312.
27. Evans HL, Lefrak SN, Lyman J, Smith RL, Chong TW, McElearney ST, Schulman AR, Hughes MG, Raymond DP, Pruett TL et al. Cost of Gram-negative resistance. Crit Care Med 2007; 35: 89-95.
28. Haley RW, Culver DH, White JW, Morgan WM, Emori TG, Munn VP, Hooton TM. The efficacy of infection surveillance and control programs in preventing nosocomial infection in US hospitals. Am J Epidemiol 1985; 121: 182-205.
29. Nettleman MD. Cost and cost benefit of infection control. In: Wenzel RP, editor. Prevention and Control of Nosocomial Infections. 4th ed. Philadelphia, PA, USA: Lippincott Williams & Wilkins; 2003. pp. 33-41.
30. Gopal Rao G, Jeanes A, Osman M, Aylott C, Gren J. Marketing hand hygiene in hospitals: a case study. J Hosp Infect 2002; 50: 42-47.